Delivery Order SPE2DB22D2006-SPE2DB25FW4JS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,153.17 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The contract, issued on June 2, 2025, with completion targeted for June 3, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. This delivery order is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- The Defense Logistics Agency awarded a delivery order valued at $4,165.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This competitive contract, executed on August 13, 2025, with an ultimate completion date of August 14, 2025, represents a firm fixed-price delivery order with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $18,133.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 10, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency awarded a $5,482.95 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 11, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical supply chain, providing brand-name medications and medical devices to support military and...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $10,594.36 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens on September 22, 2025, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. Repatha is a prescription medication used to lower cholesterol levels and reduce the...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- On July 22, 2025, the Defense Logistics Agency awarded a delivery order contract valued at $1,041.42 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This competitive, non-set-aside delivery order utilizes firm fixed pricing and is scheduled for completion by July 23, 2025. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $11,573.95 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This firm fixed-price delivery order, issued on September 12, 2025, with an ultimate completion date of September 15, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded without set-aside designation. AmerisourceBergen, a major...
- The Defense Logistics Agency awarded a $41,766.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, which is a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX, valued at $999,999,999.00 through December 2026), carries an ultimate completion date of August 22, 2025. This award was competitively granted with no...
- The Defense Logistics Agency awarded a $69,322.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 9, 2025. This competitive award, issued on September 8, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The place of performance is...
- SPE2DB22D2006Indefinite Delivery Contract
- SPE2DB22D2006-SPE2DB25FW4JSDelivery Order
The Defense Logistics Agency awarded a $80,596.93 delivery order contract to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Repatha 140 mg/ml SureClick auto-injector pens. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of September 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement and maintains extensive contracts with the Defense Logistics Agency to support military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Repatha is a PCSK9 inhibitor used in cardiovascular disease management, reflecting the contractor's portfolio of specialty medications across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $80.6k | 9/26/25 |